Cullinan's zipalertinib combo meets PFS endpoint in Phase 3 REZILIENT3 trial

Cullinan Therapeutics, Inc.

REZILIENT3 Phase 3 trial (285 patients) met primary endpoint of PFS at planned interim analysis; statistically significant and clinically meaningful improvement.
Zipalertinib plus platinum-based chemotherapy vs chemo alone in first-line EGFR exon 20 insertion NSCLC; safety manageable.
Independent Data Monitoring Committee recommended unblinding; trial continues for efficacy/safety monitoring.
Taiho and Cullinan plan to pursue U.S. FDA approval for the combination in first-line setting pending discussions.
Full results to be submitted for presentation at an upcoming international medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.